College of Pharmacy, JE 2491, Univ Lille Nord de France, 3 Rue du Prof Laguesse, 59006 Lille, France.
Int J Pharm. 2010 Jan 4;383(1-2):123-31. doi: 10.1016/j.ijpharm.2009.09.012. Epub 2009 Sep 11.
The aim of this study was to better understand the importance of the "microparticle mass:bulk fluid volume" ratio during in vitro drug release measurements from PLGA microparticles. Initially porous/non-porous, ibuprofen/lidocaine/propranolol HCl-loaded systems were exposed to phosphate buffer pH 7.4 in agitated test tubes, varying the microparticle concentration from 5:1 to 20:1mg:mL. Interestingly, drug release was virtually unaffected by the "microparticle mass:bulk fluid volume" ratio in the case of initially porous, ibuprofen-loaded microparticles, exhibiting complete drug release within about 1 week. Optical microscopy, SEM, DSC and pH measurements of the bulk fluid revealed no major impact of the microparticle concentration on the systems' properties within the first couple of days. However, a more rapid and pronounced decrease in the pH of the release medium occurred after 10-14 d at elevated "microparticle mass:bulk fluid volume" ratios. This resulted in an accelerated: (i) decrease in the glass transition temperature, (ii) microparticle agglomeration, and (iii) increase in the internal and external microparticle porosity. Importantly, this phenomenon did not significantly affect drug release from initially porous, lidocaine-loaded microparticles, exhibiting complete release within about 18 d. In contrast, drug release became significantly faster at higher "microparticle mass:bulk fluid volume" ratios in the case of initially non-porous, lidocaine-loaded microparticles and initially porous, propranolol HCl-loaded systems, exhibiting complete release after 1 and 2 months, respectively. Thus, depending on the type of system, the "microparticle mass:bulk fluid volume" ratio may or may not affect the observed release kinetics in vitro. This should be carefully taken into account when defining the experimental conditions for drug release measurements from this type of advanced drug delivery systems.
本研究的目的是更好地理解在 PLGA 微球体外药物释放测量中“微粒质量:悬浮液体积”比例的重要性。最初的多孔/非多孔、布洛芬/利多卡因/盐酸普萘洛尔负载系统在搅拌试管中暴露于 pH7.4 的磷酸盐缓冲液中,微球浓度从 5:1 到 20:1mg:mL 变化。有趣的是,对于最初多孔的布洛芬负载微球,药物释放几乎不受“微粒质量:悬浮液体积”比例的影响,在大约 1 周内完全释放药物。光学显微镜、SEM、DSC 和悬浮液 pH 值测量显示,在最初的几天内,微球浓度对系统性质没有重大影响。然而,在 10-14 天后,在较高的“微粒质量:悬浮液体积”比例下,释放介质的 pH 值下降得更快、更明显。这导致:(i)玻璃化转变温度的加速降低,(ii)微球团聚,以及 (iii)内部和外部微球孔隙率的增加。重要的是,这种现象并没有显著影响最初多孔的利多卡因负载微球的药物释放,大约 18 天内完全释放。相比之下,在最初非多孔的利多卡因负载微球和最初多孔的盐酸普萘洛尔负载系统中,药物释放在较高的“微粒质量:悬浮液体积”比例下变得明显更快,分别在 1 个月和 2 个月后完全释放。因此,取决于系统的类型,“微粒质量:悬浮液体积”比例可能会或可能不会影响体外观察到的释放动力学。在定义这种类型的先进药物输送系统的药物释放测量的实验条件时,应仔细考虑这一点。